Recent advances in esophageal squamous cell precancerous conditions: A review. Issue 50 (16th December 2022)

• Record Type: Journal Article
• Authors: Wen, Tianjiao; Wang, Wei; Chen, Xinran
• Is Part Of: Medicine. Volume 101:Issue 50(2022)
• Page Start: e32192
• Publication Date: 2022-12-16
• Subjects: biomarkers -- endoscopy -- Esophageal squamous cell carcinoma -- precancerous condition; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000032192
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Esophageal squamous cell carcinoma (ESCC) is a common cancer in many developing countries in Asia and Africa, with a 5-year survival rate of approximately 20%. Most cases are diagnosed at an advanced age when there is no effective treatment strategy. Esophageal precancerous conditions have a much better prognosis, with a 5-year survival rate of over 90% by endoscopic diagnosis and treatment. Nevertheless, limitations, contraindications, and lymph node metastasis incompetency of endoscopy. Thus, the diagnosis and treatment of esophageal precancerous lesions remain a significant challenge. Biomarker investigations provide opportunities for target detection and therapy. Additionally, drug development is ongoing. Changes in lifestyle habits, such as diet balance, smoking and alcohol cessation, are beneficial for the prognosis of esophageal precancerous lesions. Collectively, multiple and sequential diagnoses and treatments are essential for curing esophageal precancerous lesions and reducing the incidence and mortality of ESCC.